CA2575340A1 - Macrocyclic beta-secretase inhibitors - Google Patents

Macrocyclic beta-secretase inhibitors Download PDF

Info

Publication number
CA2575340A1
CA2575340A1 CA002575340A CA2575340A CA2575340A1 CA 2575340 A1 CA2575340 A1 CA 2575340A1 CA 002575340 A CA002575340 A CA 002575340A CA 2575340 A CA2575340 A CA 2575340A CA 2575340 A1 CA2575340 A1 CA 2575340A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
effective amount
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002575340A
Other languages
English (en)
French (fr)
Inventor
Andrew W. Stamford
Ying Huang
Guoqing Li
Corey O. Strickland
Johannes H. Voigt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2575340A1 publication Critical patent/CA2575340A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002575340A 2004-07-28 2005-07-26 Macrocyclic beta-secretase inhibitors Abandoned CA2575340A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59189904P 2004-07-28 2004-07-28
US60/591,899 2004-07-28
PCT/US2005/026468 WO2006014944A1 (en) 2004-07-28 2005-07-26 Macrocyclic beta-secretase inhibitors

Publications (1)

Publication Number Publication Date
CA2575340A1 true CA2575340A1 (en) 2006-02-09

Family

ID=35106859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002575340A Abandoned CA2575340A1 (en) 2004-07-28 2005-07-26 Macrocyclic beta-secretase inhibitors

Country Status (12)

Country Link
US (2) US7652003B2 (https=)
EP (1) EP1781644B1 (https=)
JP (1) JP2008508289A (https=)
CN (1) CN101027297B (https=)
AR (1) AR050184A1 (https=)
AT (1) ATE396990T1 (https=)
CA (1) CA2575340A1 (https=)
DE (1) DE602005007245D1 (https=)
ES (1) ES2306200T3 (https=)
MX (1) MX2007001102A (https=)
TW (1) TWI297337B (https=)
WO (1) WO2006014944A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
KR20070102514A (ko) * 2005-01-13 2007-10-18 노파르티스 아게 Ｂａｃｅ 억제제로서 유용한 마크로시클릭 화합물
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
PE20070135A1 (es) 2005-06-14 2007-03-09 Schering Corp Compuestos heterociclicos como inhibidores de aspartil proteasas
AU2006259675A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
PE20080155A1 (es) 2006-06-12 2008-03-10 Schering Corp Compuestos heterociclicos como inhibidores de aspartil-proteasa
BRPI0715437A2 (pt) * 2006-07-20 2013-04-16 Novartis Ag lactamas macrocÍclicas
ATE549923T1 (de) 2006-10-06 2012-04-15 Merck Sharp & Dohme Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
MX2010005028A (es) 2007-11-05 2010-05-27 Schering Corp Moduladores de gamma secretasa.
EP2227471A1 (en) 2007-12-11 2010-09-15 Schering Corporation Gamma secretase modulators
CA2723222C (en) 2008-04-22 2013-04-02 Schering Corporation Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.
WO2010075204A2 (en) 2008-12-22 2010-07-01 Schering Corporation Gamma secretase modulators
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2010147973A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147975A1 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011044187A1 (en) 2009-10-08 2011-04-14 Schering Corporation Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485590B1 (en) 2009-10-08 2015-01-07 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
EP2485920B1 (en) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2694489B1 (en) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN103874496A (zh) 2011-08-22 2014-06-18 默沙东公司 作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
WO2014056816A1 (en) 2012-10-10 2014-04-17 F. Hoffmann-La Roche Ag COMBINATION OF AN Aβ ANTIBODY AND A BACE INHIBITOR
EP2908824B1 (en) 2012-10-17 2018-05-02 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9422277B2 (en) 2012-10-17 2016-08-23 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
CN105175488A (zh) * 2015-09-07 2015-12-23 西北农林科技大学 一种具有抗老年痴呆症活性的化合物及其制备方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500772A (ja) 1987-10-21 1991-02-21 ジ・アップジョン・カンパニー （１‐アミノ‐２‐ヒドロキシ‐２‐ヘテロサイクリック）エチル基を含有するレニン抑制物質類
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
JP2004502664A (ja) 2000-06-30 2004-01-29 イーラン　ファーマスーティカルズ、インコーポレイテッド アルツハイマー病処置用化合物
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1389194A2 (en) 2001-04-27 2004-02-18 Vertex Pharmaceuticals Incorporated Inhibitors of bace
ATE323084T1 (de) * 2001-06-12 2006-04-15 Elan Pharm Inc Für die behandlung von alzheimer krankheit geeignete makrocyclen
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US20040171614A1 (en) * 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
ATE443043T1 (de) * 2002-11-12 2009-10-15 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
WO2004062625A2 (en) * 2003-01-07 2004-07-29 Merck & Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
RU2006144075A (ru) * 2004-06-16 2008-07-27 Вайет (Us) ДИФЕНИЛИМИДАЗОПИРИМИДИН И -ИМИДАЗОЛАМИНЫ КАК ИНГИБИТОРЫ β-СЕКРЕТАЗЫ
BRPI0512213A (pt) * 2004-06-16 2008-02-19 Wyeth Corp método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
TW200738683A (en) 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
AU2006266167A1 (en) 2005-06-30 2007-01-11 Wyeth Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
JP2009509957A (ja) * 2005-09-26 2009-03-12 ワイス β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物
CN101460480A (zh) 2006-04-05 2009-06-17 阿斯利康(瑞典)有限公司 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途
TW200815443A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds I
TW200815449A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds II
TW200815447A (en) 2006-06-14 2008-04-01 Astrazeneca Ab Novel compounds IV
TW200808796A (en) 2006-06-14 2008-02-16 Astrazeneca Ab New compounds III
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds

Also Published As

Publication number Publication date
AR050184A1 (es) 2006-10-04
CN101027297B (zh) 2010-09-08
US7652003B2 (en) 2010-01-26
US20060040948A1 (en) 2006-02-23
US20100178294A1 (en) 2010-07-15
EP1781644A1 (en) 2007-05-09
US8012953B2 (en) 2011-09-06
JP2008508289A (ja) 2008-03-21
ATE396990T1 (de) 2008-06-15
CN101027297A (zh) 2007-08-29
DE602005007245D1 (https=) 2008-07-10
TWI297337B (en) 2008-06-01
EP1781644B1 (en) 2008-05-28
WO2006014944A1 (en) 2006-02-09
TW200607807A (en) 2006-03-01
HK1102328A1 (en) 2007-11-16
ES2306200T3 (es) 2008-11-01
MX2007001102A (es) 2007-04-13

Similar Documents

Publication Publication Date Title
EP1781644B1 (en) Macrocyclic beta-secretase inhibitors
EP1781625B1 (en) Substituted amide beta secretase inhibitors
CN103429590B (zh) 作为bace1和/或bace2抑制剂的1，4硫氮杂*/砜
CN104870000A (zh) 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
CN102066380A (zh) 作为bace-1抑制剂的苯基-取代的2-亚氨基-3-甲基吡咯并嘧啶酮化合物、组合物及其用途
JP2010535762A (ja) ガンマセクレターゼモジュレーター
JP6251249B2 (ja) Ｂａｃｅ１阻害薬としての５−アミノ［１，４］チアジン類
US20110294756A1 (en) Gamma secretase modulators
US20100298359A1 (en) Gamma secretase modulators
CN101878202A (zh) γ-分泌酶调节剂
KR20140051823A (ko) 결정질 옥사진 유도체 및 bace 억제제로서의 그의 용도
US8809318B2 (en) Gamma secretase modulators
JP2012513400A (ja) γ−セクレターゼ調節剤
US20120238546A1 (en) Gamma secretase modulators
WO2015066696A1 (en) Fused morphlinopyrimidines and methods of use thereof
US20120245158A1 (en) Gamma secretase modulators
HK1102328B (en) Macrocyclic beta-secretase inhibitors
US9489013B2 (en) C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use
US11021448B2 (en) 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases
US20120232108A1 (en) Gamma secretase modulators
HK1190702A (en) 1,4 thiazepines/sulfones as bace1 and/or bace2 inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130717